Thrombophilia Testing After VTE and in Related Clinical Contexts: Is It Necessary, and Does It Change Management? Appraisal of Evidence, Guidelines, and Clinical Yield

Thrombophilia testing is commonly performed after venous thromboembolism (VTE), yet its clinical value is frequently overestimated. This narrative critical review synthesizes key observational studies, systematic reviews, and contemporary clinical practice guidelines addressing the utility, timing, and management implications of thrombophilia testing after VTE, as well as in related clinical settings where analogous testing decisions arise such as cryptogenic arterial stroke and recurrent pregnancy loss. Evidence and recommendations were selected based on their clinical relevance to anticoagulation decisions, recurrence risk assessment, and patient-specific management, with particular attention to contemporary guidelines from the American Society of Hematology, American College of Chest Physicians, National Institute for Health and Care Excellence, and British Society for Haematology. The strength and certainty of the evidence underlying these recommendations were also considered, recognizing that several recommendations are conditional and are supported by very low certainty evidence and decision modeling. Overall, the available evidence synthesized in this review indicates that anticoagulation decisions are determined primarily by whether the event was provoked or unprovoked, the risks of recurrence and bleeding, and patient-specific clinical factors rather than by the presence of most inherited thrombophilias. Although thrombophilia testing often identifies laboratory abnormalities, it rarely changes clinical management while increasing healthcare costs and the potential for unnecessary treatment and patient anxiety. Antiphospholipid syndrome remains the major exception because its diagnosis directly influences anticoagulant selection, treatment duration, and pregnancy management. This review also considers the importance of appropriate test timing, the effects of anticoagulant therapy on test interpretation, and the role of thrombophilia testing in selected clinical scenarios. Based on the available evidence, we propose a practical, management-oriented approach in which testing is reserved for situations where the results are expected to influence therapeutic decision making, thereby promoting high-value, evidence-based patient care.